Scarica l'app Stockscreener
686.36
6.21%
-45.41
Dopo l'orario di chiusura:
681.54
-4.82
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$731.77
Aprire:
$705.11
Volume 24 ore:
1.83M
Relative Volume:
2.60
Capitalizzazione di mercato:
$71.96B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
16.51
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
-8.07%
1M Prestazione:
-6.96%
6M Prestazione:
+5.12%
1 anno Prestazione:
+20.64%
Intervallo 1D:
$668.85
$708.80
Intervallo di 1 settimana:
$668.85
$767.21
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st
Truist cuts Regeneron stock price target on FDA approval delay By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's
Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8%Here's What Happened - MarketBeat
Regeneron Pharmaceuticals Delivers 19% Revenue Growth in Q1 2026 - AlphaStreet
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe - Benzinga
Regeneron Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Regeneron shares fall 5% on Eylea sales decline, regulatory delays By Investing.com - Investing.com Canada
Raymond James cuts Regeneron stock price target on Eylea HD miss - Investing.com Canada
Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today - Benzinga
Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness - Reuters
Intel, NXP Semiconductors, Seagate, Bloom Energy, Avis, Regeneron, Robinhood, and More Stock Movers - Barron's
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength - Yahoo Finance
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares. - marketscreener.com
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025. - marketscreener.com
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings - BioSpace
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength (NASDAQ:REGN) - Seeking Alpha
Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com
Regeneron drops despite Q1 beat, $3B share buyback program - MSN
Regeneron shares slide despite Q1 beat - Yahoo! Finance Canada
Regeneron beats quarterly estimates on strong Dupixent demand - WHTC
Regeneron Pharmaceuticals (REGN) Reports Strong Q1 2026 Earnings and Announces $3B Buyback - GuruFocus
Is Regeneron (REGN) Still 23.3% Undervalued After Q1 2026? Non-G - GuruFocus
Regeneron Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:REGN) 2026-04-29 - Seeking Alpha
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock - TechStock²
Regeneron stock drops despite Q1 beat (REGN:NASDAQ) - Seeking Alpha
Regeneron Tops Q1 Estimates on Dupixent Momentum - Yahoo Finance
Regeneron (REGN) Reports Strong Q1 Revenue and New Drug Pricing Initiative - GuruFocus
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance Australia
Regeneron beats quarterly results estimates on strong Dupixent demand - Yahoo Finance
Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Regeneron beats first quarter estimates on Dupixent strength By Investing.com - Investing.com Nigeria
REGENERON PHARMACEUTICALS ($REGN) Releases Q1 2026 Earnings - Quiver Quantitative
Mitsubishi UFJ Trust & Banking Corp Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Reports First Quarter 2026 Financial and Operating Results - The Manila Times
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 - Yahoo Finance
Regeneron: Q1 Earnings Snapshot - KTVB
Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron strikes deal with Trump administration to cut drug prices - MSN
Is It Too Late To Consider Regeneron (REGN) After Its 29% One-Year Rally? - Yahoo Finance
Hemophilia B Pipeline Set for Transformational Breakthroughs - openPR.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Will Regeneron Pharmaceuticals Stock React To Its Upcoming Earnings? - Trefis
Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.13%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):